NCT06434480

SBRT in HCC With Oligoprogression on First-line Immunotherapy

Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma With Oligoprogression on First-line Immunotherapy

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Chinese University of Hong Kong · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

HCC is a huge healthcare burden in Hong Kong and is one of the top 5 cancers in terms of incidence and mortality in Hong Kong. Patients with advanced HCC are treated with immunotherapy-based as first-line treatment as a standard of care. At the moment, there is limited evidence to guide subsequent treatments after patients progressed on immunotherapy. Oligoprogression is a term used to describe patients who had limited progression (usually less than 3 sites) on systemic therapy, with the rest of the lesions controlled. Previous studies in non-HCCs have shown that addition of locoregional treatment (e.g. radiotherapy) may prolong the use of systemic therapy, resulting in improved survival, but this has been relatively unexplored for HCC. In this prospective, single-arm study, we aim to evaluate the treatment outcome, efficacy and safety of the addition of radiotherapy to oligoprogressive sites for patients who had limited progression on First-line Immunotherapy.

Conditions

• HCC

Interventions

Type	Name	Description
RADIATION	Stereotactic Body Radiation Therapy (SBRT)	* For intrahepatic progression: 27.5-50Gy in 5 fractions over 2 weeks will be given. * For extrahepatic progression: an aim to give ablative dose will be given.

Timeline

• Start date: 2024-06-21
• Primary completion: 2027-03-01
• Completion: 2028-03-01
• First posted: 2024-05-30
• Last updated: 2026-03-04

Locations

1 site across 1 country: Hong Kong